Charles Schwab Investment Management Inc. Has $10.24 Million Stock Holdings in Artivion, Inc. (NYSE:AORT)

Charles Schwab Investment Management Inc. boosted its position in Artivion, Inc. (NYSE:AORT) by 2.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 358,192 shares of the company’s stock after buying an additional 8,343 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Artivion were worth $10,241,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of AORT. Quest Partners LLC raised its position in Artivion by 2,481,700.0% in the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock valued at $661,000 after buying an additional 24,817 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Artivion by 6.6% during the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock worth $280,000 after purchasing an additional 653 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Artivion by 28.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock worth $522,000 after purchasing an additional 4,295 shares during the last quarter. FMR LLC increased its position in shares of Artivion by 28.0% during the 3rd quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after purchasing an additional 25,176 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Artivion by 543.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock worth $761,000 after purchasing an additional 24,130 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AORT shares. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Stifel Nicolaus lowered their price target on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Finally, Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.40.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 5,335 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $145,698.85. Following the completion of the sale, the senior vice president now directly owns 149,799 shares in the company, valued at $4,091,010.69. The trade was a 3.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Lance A. Berry sold 3,259 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $89,003.29. Following the completion of the sale, the chief financial officer now owns 75,805 shares of the company’s stock, valued at $2,070,234.55. This trade represents a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,799 shares of company stock worth $2,356,223 in the last ninety days. 8.10% of the stock is owned by company insiders.

Artivion Stock Performance

Shares of NYSE AORT opened at $24.47 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 12 month low of $19.36 and a 12 month high of $32.33. The stock has a 50 day moving average of $28.14 and a 200-day moving average of $27.64. The company has a market capitalization of $1.03 billion, a P/E ratio of -1,223.50 and a beta of 1.79.

Artivion (NYSE:AORT) last issued its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. As a group, equities research analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.